Immunome (NASDAQ:IMNM) Director Acquires $21,550.00 in Stock

Immunome, Inc. (NASDAQ:IMNM) Director Jean Jacques Bienaime acquired 1,000 shares of the stock in a transaction that occurred on Wednesday, March 11th. The stock was purchased at an average price of $21.55 per share, for a total transaction of $21,550.00. Following the completion of the acquisition, the director owned 38,415 shares in the company, valued at $827,843.25. The trade was a 2.67% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Immunome Price Performance

NASDAQ IMNM opened at $20.36 on Friday. The company has a market cap of $2.30 billion, a PE ratio of -8.41 and a beta of 2.12. The stock’s 50 day simple moving average is $22.73 and its 200-day simple moving average is $18.12. Immunome, Inc. has a 1-year low of $5.15 and a 1-year high of $27.65.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.10). Immunome had a negative return on equity of 57.61% and a negative net margin of 1,687.08%. On average, equities research analysts anticipate that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on IMNM. Evercore raised their price target on shares of Immunome from $18.00 to $40.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 16th. Truist Financial assumed coverage on shares of Immunome in a research note on Monday, December 1st. They set a “buy” rating and a $36.00 price objective for the company. Wall Street Zen downgraded shares of Immunome from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Craig Hallum raised their target price on shares of Immunome from $33.00 to $36.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Finally, Leerink Partners set a $40.00 target price on Immunome in a report on Monday, December 15th. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Immunome currently has an average rating of “Moderate Buy” and an average target price of $33.45.

Institutional Investors Weigh In On Immunome

A number of hedge funds have recently modified their holdings of IMNM. T. Rowe Price Investment Management Inc. raised its stake in Immunome by 59.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock worth $288,305,000 after purchasing an additional 5,003,824 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Immunome by 8,659.2% in the 4th quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock valued at $61,341,000 after buying an additional 2,823,144 shares during the period. Primecap Management Co. CA grew its stake in shares of Immunome by 55.2% in the 4th quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock valued at $100,643,000 after buying an additional 1,667,432 shares during the period. Balyasny Asset Management L.P. acquired a new stake in shares of Immunome during the 4th quarter worth approximately $30,710,000. Finally, Sofinnova Investments Inc. increased its holdings in shares of Immunome by 271.2% during the 4th quarter. Sofinnova Investments Inc. now owns 1,618,477 shares of the company’s stock worth $34,765,000 after buying an additional 1,182,426 shares during the last quarter. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.